دورية أكاديمية

PCR-based analysis of PD-L1 RNA expression in lung cancer: comparison with commonly used immunohistochemical assays.

التفاصيل البيبلوغرافية
العنوان: PCR-based analysis of PD-L1 RNA expression in lung cancer: comparison with commonly used immunohistochemical assays.
المؤلفون: Venina AR; N.N. Petrov Institute of Oncology, St.-Petersburg 197758, Russia., Ivantsov AO; N.N. Petrov Institute of Oncology, St.-Petersburg 197758, Russia., Iyevleva AG; N.N. Petrov Institute of Oncology, St.-Petersburg 197758, Russia. Electronic address: aglayai@inbox.ru., Kuligina ES; N.N. Petrov Institute of Oncology, St.-Petersburg 197758, Russia., Preobrazhenskaya EV; N.N. Petrov Institute of Oncology, St.-Petersburg 197758, Russia., Yurlov DO; N.N. Petrov Institute of Oncology, St.-Petersburg 197758, Russia., Rawlinson KE; N.N. Petrov Institute of Oncology, St.-Petersburg 197758, Russia., Kosmin AV; N.N. Petrov Institute of Oncology, St.-Petersburg 197758, Russia., Savelov NA; Moscow City Oncological Hospital №62, Moscow 143423, Russia., Raskin GA; S. Berezin International Institute of Biological Systems, Saint-Petersburg 197758, Russia., Imyanitov EN; N.N. Petrov Institute of Oncology, St.-Petersburg 197758, Russia; St.-Petersburg Pediatric Medical University, St.-Petersburg 194100, Russia; I.I. Mechnikov North-Western Medical University, St.-Petersburg 191015, Russia.
المصدر: Annals of diagnostic pathology [Ann Diagn Pathol] 2022 Aug; Vol. 59, pp. 151968. Date of Electronic Publication: 2022 May 06.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: W.B. Saunders Co Country of Publication: United States NLM ID: 9800503 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1532-8198 (Electronic) Linking ISSN: 10929134 NLM ISO Abbreviation: Ann Diagn Pathol Subsets: MEDLINE
أسماء مطبوعة: Original Publication: Philadelphia, PA : W.B. Saunders Co., c1997-
مواضيع طبية MeSH: Carcinoma, Non-Small-Cell Lung*/diagnosis , Carcinoma, Non-Small-Cell Lung*/drug therapy , Carcinoma, Non-Small-Cell Lung*/genetics , Lung Neoplasms*/diagnosis , Lung Neoplasms*/genetics, Antibodies ; B7-H1 Antigen/metabolism ; Biomarkers, Tumor/metabolism ; Humans ; Polymerase Chain Reaction ; RNA
مستخلص: Background: PD-L1 testing is currently performed by immunohistochemistry (IHC). We questioned whether the results of PCR-based measurement of PD-L1 RNA expression correlate with IHC scores obtained by different commercial assays.
Materials and Methods: 167 consecutive non-squamous non-small cell lung carcinomas (NSCLCs) were analyzed for PD-L1 RNA expression and 22C3, SP263, and SP142 IHC scoring using recommended cut-offs. RNA expression was divided into low, moderate, and high categories.
Results: RNA and protein expression demonstrated moderate correlation as continuous variables. Using prespecified RNA cut-offs, PCR testing showed a high negative predictive value towards the IHC analysis: the share of PD-L1 protein-negative tumors among cases classified as PD-L1-low by the PCR test reached 92-99% for all three antibodies. Meanwhile, about half of cases with moderate to high PD-L1 RNA expression had IHC staining in less than 1% tumor cells as determined by 22C3 or SP263 antibodies. Among the 51 discordant cases, which had <1% tumor staining by both 22C3 and SP263 clones but high RNA level, 29 (57%) showed ≥1% positive immune cells by SP263 and/or 22C3, 14 cases (27%) had detectable IHC expression in 0.1-0.9% tumor or immune cells by SP263 and/or 22C3, and 8 (16%) were entirely negative by IHC.
Conclusion: Some NSCLCs demonstrate readily detectable PD-L1 expression on the level of RNA, but fall below commonly accepted cut-offs by IHC. It remains to be studied whether these discrepancies are attributed to technical or biological reasons. Clinical sensitivity of these tumors to immune therapy deserves additional investigations.
(Copyright © 2022 Elsevier Inc. All rights reserved.)
فهرسة مساهمة: Keywords: Immune checkpoint inhibitors; Non-small cell lung cancer; PD-L1 RNA expression; PD-L1 immunohistochemistry
المشرفين على المادة: 0 (Antibodies)
0 (B7-H1 Antigen)
0 (Biomarkers, Tumor)
63231-63-0 (RNA)
تواريخ الأحداث: Date Created: 20220514 Date Completed: 20220628 Latest Revision: 20220628
رمز التحديث: 20221213
DOI: 10.1016/j.anndiagpath.2022.151968
PMID: 35567888
قاعدة البيانات: MEDLINE
الوصف
تدمد:1532-8198
DOI:10.1016/j.anndiagpath.2022.151968